Literature DB >> 8553666

Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients.

Z Y Tang1, Y Q Uy, X D Zhou, Z C Ma, J Z Lu, Z Y Lin, K D Liu, S L Ye, B H Yang, H W Wang.   

Abstract

The poor prognosis of hepatocellular carcinoma (HCC) was partly a result of the majority of unresectable HCCs in clinical patients. Fortunately, with the progress of regional cancer therapies and multimodality treatment, some of the localized unresectable HCCs were converted to resectable ones. During the period 1960-1994, 72 of the 663 patients with surgically verified unresectable HCCs have been converted to resectable. Successful cytoreduction with median diameter reduced from 10 cm to 5 cm was mainly a result of the triple or double combination treatment with hepatic artery ligation, hepatic artery cannulation with infusion, radioimmunotherapy, and fractionated regional radiotherapy. The interval between the first operation and the sequential resection was 5 months. The operative mortality was 1.4% for sequential resection, and the 5-year survival was 62.1%. Analysis of factor influencing sequential resection rate revealed HCCs that were single nodule, well encapsulated, situated at right lobe or hepatic hilum, associated with micronodular cirrhosis, and treated with triple or double combination modalities had higher sequential resection rate as compared to their counterparts. Analysis of factors influencing survival after sequential resection revealed that HCCs with a solitary tumor confined in one lobe, without tumor embolus, and without residual cancer in specimen of sequential resection, had longer survival. It is suggested that localized unresectable, solitary, well encapsulated, right lobe or hilar HCC, associated with micronodular cirrhosis, will be good candidates for cytoreduction and sequential resection; and HCCs with unilateral involvement, without tumor embolus, and with complete necrosis of tumor after multimodality treatment favored better prognosis.

Entities:  

Mesh:

Year:  1995        PMID: 8553666     DOI: 10.1007/bf00299771

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

1.  Cytoreduction and sequential resection: a hope for unresectable primary liver cancer.

Authors:  Z Y Tang; Y Q Yu; X D Zhou; Z C Ma; J Z Lu; K D Liu; Z Y Lin; B H Yang; Z Fan; Z Hou
Journal:  J Surg Oncol       Date:  1991-05       Impact factor: 3.454

2.  Evolution of surgery in the treatment of hepatocellular carcinoma from the 1950s to the 1990s.

Authors:  Z Y Tang; Y Q Yu; X D Zhou
Journal:  Semin Surg Oncol       Date:  1993 Jul-Aug

3.  Preoperative irradiation and chemotherapy for initially unresectable hepatoblastoma.

Authors:  A D Shafer; P M Selinkoff
Journal:  J Pediatr Surg       Date:  1977-12       Impact factor: 2.545

4.  Tumor imaging and targeting therapy for hepatocellular carcinoma. Preliminary results of experimental and clinical studies.

Authors:  Z Y Tang; K D Lui; Y D Guo; Z C Ma; D Yu; Z Y Yu; Y M Boa; J Z Lu; Z Y Lin; Y Q Yu
Journal:  Chin Med J (Engl)       Date:  1986-11       Impact factor: 2.628

5.  Reoperative primary liver cancer. Report of 28 cases.

Authors:  H Chen; M C Wu
Journal:  Chin Med J (Engl)       Date:  1987-10       Impact factor: 2.628

6.  Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases.

Authors:  T Higuchi; M Kikuchi; M Okazaki
Journal:  Cancer       Date:  1994-05-01       Impact factor: 6.860

7.  Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma.

Authors:  I O Ng; E C Lai; S T Fan; M Ng; A S Chan; M K So
Journal:  Cancer       Date:  1994-05-01       Impact factor: 6.860

8.  Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion.

Authors:  Z Fan; Z Tang; K Liu; D Zhou; J Lu; A Yuan; H Zhao
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

9.  Detection of alpha-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma.

Authors:  M Matsumura; Y Niwa; N Kato; Y Komatsu; S Shiina; T Kawabe; T Kawase; H Toyoshima; M Ihori; Y Shiratori
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

10.  Cancer statistics, 1995.

Authors:  P A Wingo; T Tong; S Bolden
Journal:  CA Cancer J Clin       Date:  1995 Jan-Feb       Impact factor: 508.702

View more
  12 in total

Review 1.  Cryosurgery in the treatment of liver metastasis from colorectal cancer.

Authors:  T S Ravikumar; R Sotomayor; R Goel
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

Review 2.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma.

Authors:  C M Lo; E C Lai; C L Liu; S T Fan; J Wong
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

Review 4.  Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).

Authors:  Hui-Chuan Sun; Jian Zhou; Zheng Wang; Xiufeng Liu; Qing Xie; Weidong Jia; Ming Zhao; Xinyu Bi; Gong Li; Xueli Bai; Yuan Ji; Li Xu; Xiao-Dong Zhu; Dousheng Bai; Yajin Chen; Yongjun Chen; Chaoliu Dai; Rongping Guo; Wenzhi Guo; Chunyi Hao; Tao Huang; Zhiyong Huang; Deyu Li; Gang Li; Tao Li; Xiangcheng Li; Guangming Li; Xiao Liang; Jingfeng Liu; Fubao Liu; Shichun Lu; Zheng Lu; Weifu Lv; Yilei Mao; Guoliang Shao; Yinghong Shi; Tianqiang Song; Guang Tan; Yunqiang Tang; Kaishan Tao; Chidan Wan; Guangyi Wang; Lu Wang; Shunxiang Wang; Tianfu Wen; Baocai Xing; Bangde Xiang; Sheng Yan; Dinghua Yang; Guowen Yin; Tao Yin; Zhenyu Yin; Zhengping Yu; Bixiang Zhang; Jialin Zhang; Shuijun Zhang; Ti Zhang; Yamin Zhang; Yubao Zhang; Aibin Zhang; Haitao Zhao; Ledu Zhou; Wu Zhang; Zhenyu Zhu; Shukui Qin; Feng Shen; Xiujun Cai; Gaojun Teng; Jianqiang Cai; Minshan Chen; Qiang Li; Lianxin Liu; Weilin Wang; Tingbo Liang; Jiahong Dong; Xiaoping Chen; Xuehao Wang; Shusen Zheng; Jia Fan
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

5.  Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases.

Authors:  Xin-Da Zhou; Zhao-You Tang; Zeng-Chen Ma; Jia Fan; Zhi-Quan Wu; Lun-Xiu Qin; Jian Zhou; Yao Yu; Hui-Chuan Sun; Shuang-Jian Qiu
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-18       Impact factor: 4.553

6.  Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Yung-Chih Lai; Cheng-Yen Shih; Chin-Ming Jeng; Sien-Sing Yang; Jui-Ting Hu; Yung-Chuan Sung; Han-Ting Liu; Shaw-Min Hou; Chi-Hwa Wu; Tzen-Kwan Chen
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

7.  Salvage surgery following downstaging of unresectable hepatocellular carcinoma.

Authors:  Wan-yee Lau; Stephen K W Ho; Simon C H Yu; Eric C H Lai; Choong-tsek Liew; Thomas W T Leung
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

8.  Surgery for large primary liver cancer more than 10 cm in diameter.

Authors:  Xin-Da Zhou; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Jia Fan; Lun-Xiu Qin; Bo-Heng Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-30       Impact factor: 4.553

9.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).

Authors:  Jian Zhou; Hui-Chuan Sun; Zheng Wang; Wen-Ming Cong; Jian-Hua Wang; Meng-Su Zeng; Jia-Mei Yang; Ping Bie; Lian-Xin Liu; Tian-Fu Wen; Guo-Hong Han; Mao-Qiang Wang; Rui-Bao Liu; Li-Gong Lu; Zheng-Gang Ren; Min-Shan Chen; Zhao-Chong Zeng; Ping Liang; Chang-Hong Liang; Min Chen; Fu-Hua Yan; Wen-Ping Wang; Yuan Ji; Wen-Wu Cheng; Chao-Liu Dai; Wei-Dong Jia; Ya-Ming Li; Ye-Xiong Li; Jun Liang; Tian-Shu Liu; Guo-Yue Lv; Yi-Lei Mao; Wei-Xin Ren; Hong-Cheng Shi; Wen-Tao Wang; Xiao-Ying Wang; Bao-Cai Xing; Jian-Ming Xu; Jian-Yong Yang; Ye-Fa Yang; Sheng-Long Ye; Zheng-Yu Yin; Bo-Heng Zhang; Shui-Jun Zhang; Wei-Ping Zhou; Ji-Ye Zhu; Rong Liu; Ying-Hong Shi; Yong-Sheng Xiao; Zhi Dai; Gao-Jun Teng; Jian-Qiang Cai; Wei-Lin Wang; Jia-Hong Dong; Qiang Li; Feng Shen; Shu-Kui Qin; Jia Fan
Journal:  Liver Cancer       Date:  2018-06-14       Impact factor: 11.740

10.  Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Authors:  Jian Zhou; Huichuan Sun; Zheng Wang; Wenming Cong; Jianhua Wang; Mengsu Zeng; Weiping Zhou; Ping Bie; Lianxin Liu; Tianfu Wen; Guohong Han; Maoqiang Wang; Ruibao Liu; Ligong Lu; Zhengang Ren; Minshan Chen; Zhaochong Zeng; Ping Liang; Changhong Liang; Min Chen; Fuhua Yan; Wenping Wang; Yuan Ji; Jingping Yun; Dingfang Cai; Yongjun Chen; Wenwu Cheng; Shuqun Cheng; Chaoliu Dai; Wenzhi Guo; Baojin Hua; Xiaowu Huang; Weidong Jia; Yaming Li; Yexiong Li; Jun Liang; Tianshu Liu; Guoyue Lv; Yilei Mao; Tao Peng; Weixin Ren; Hongcheng Shi; Guoming Shi; Kaishan Tao; Wentao Wang; Xiaoying Wang; Zhiming Wang; Bangde Xiang; Baocai Xing; Jianming Xu; Jiamei Yang; Jianyong Yang; Yefa Yang; Yunke Yang; Shenglong Ye; Zhengyu Yin; Bixiang Zhang; Boheng Zhang; Leida Zhang; Shuijun Zhang; Ti Zhang; Yongfu Zhao; Honggang Zheng; Jiye Zhu; Kangshun Zhu; Rong Liu; Yinghong Shi; Yongsheng Xiao; Zhi Dai; Gaojun Teng; Jianqiang Cai; Weilin Wang; Xiujun Cai; Qiang Li; Feng Shen; Shukui Qin; Jiahong Dong; Jia Fan
Journal:  Liver Cancer       Date:  2020-11-11       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.